Page last updated: 2024-11-08

fr 7534

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

FR 7534: calcium antagonist structurally similar to nifedipine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID173874
SCHEMBL ID7379644
MeSH IDM0071342

Synonyms (13)

Synonym
nsc335670
nsc-335670
62760-70-7
fr-7534
fr 7534
1,4-dihydro-2-hydroxymethyl-4-(m-nitrophenyl)-6-methyl-3,5-pyridine dicarboxylic acid diethyl ester
nsc 335670
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2-(hydroxymethyl)-6-methyl-4-(3-nitrophenyl)-, diethyl ester
SCHEMBL7379644
LWTWJBUKUVHABE-UHFFFAOYSA-N
diethyl 1,4-dihydro-2-(hydroxymethyl)-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
diethyl 2-methyl-4-(3-nitrophenyl)-6-hydroxymethyl-1,4-dihydropyridine-3,5-dicarboxylate
DTXSID10978423

Research Excerpts

Treatment

ExcerptReferenceRelevance
"FR 7534 treatment increased subepicardial, subendocardial, and transmural tissue flow by 100% in the central ischemic zone when perfusion pressure was controlled by methoxamine."( Improvement in ischemic myocardial blood flow following a new calcium antagonist.
Gross, GJ; Jolly, SR, 1980
)
0.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Voltage-dependent L-type calcium channel subunit alpha-1COryctolagus cuniculus (rabbit)IC50 (µMol)0.04900.03700.06430.1070AID478862
Voltage-dependent L-type calcium channel subunit alpha-1DRattus norvegicus (Norway rat)IC50 (µMol)0.04500.00131.991510.0000AID478861
Histamine H2 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.04500.00402.15557.2000AID478861
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID478863Selectivity ratio of IC50 for rabbit Cav1.2 to IC50 for rat Cav1.32010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
AID478861Antagonist activity at rat Cav1.3 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current by FLIPR calcium 4 assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
AID478862Antagonist activity at rabbit Cav1.2 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current by FLIPR calcium 4 assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (87.50)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.77 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]